- Home
- NXDT vs ANNX Comparison
NXDT vs ANNX Comparison
Compare NXDT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXDT
- ANNX
- Stock Information
- Founded
- NXDT 2012
- ANNX 2011
- Country
- NXDT United States
- ANNX United States
- Employees
- NXDT N/A
- ANNX N/A
- Industry
- NXDT Investment Managers
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- NXDT Finance
- ANNX Health Care
- Exchange
- NXDT Nasdaq
- ANNX Nasdaq
- Market Cap
- NXDT 223.1M
- ANNX 253.8M
- IPO Year
- NXDT N/A
- ANNX 2020
- Fundamental
- Price
- NXDT $3.45
- ANNX $2.20
- Analyst Decision
- NXDT
- ANNX Strong Buy
- Analyst Count
- NXDT 0
- ANNX 5
- Target Price
- NXDT N/A
- ANNX $13.00
- AVG Volume (30 Days)
- NXDT 133.6K
- ANNX 1.3M
- Earning Date
- NXDT 01-01-0001
- ANNX 08-14-2025
- Dividend Yield
- NXDT 9.66%
- ANNX N/A
- EPS Growth
- NXDT N/A
- ANNX N/A
- EPS
- NXDT 0.99
- ANNX N/A
- Revenue
- NXDT N/A
- ANNX N/A
- Revenue This Year
- NXDT N/A
- ANNX N/A
- Revenue Next Year
- NXDT N/A
- ANNX N/A
- P/E Ratio
- NXDT $6.41
- ANNX N/A
- Revenue Growth
- NXDT N/A
- ANNX N/A
- 52 Week Low
- NXDT $5.89
- ANNX $1.29
- 52 Week High
- NXDT $13.07
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- NXDT 35.19
- ANNX 47.48
- Support Level
- NXDT $3.50
- ANNX $2.03
- Resistance Level
- NXDT $3.86
- ANNX $2.36
- Average True Range (ATR)
- NXDT 0.26
- ANNX 0.13
- MACD
- NXDT -0.01
- ANNX 0.01
- Stochastic Oscillator
- NXDT 19.72
- ANNX 53.85
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.